WOBURN, Mass.--(BUSINESS WIRE)--Courtagen Life Sciences, Inc., a privately held life sciences company that provides innovative proteomic and genomic products and services to the life sciences industry, today announced the introduction of their first genetic tests using next generation sequencing (NGS) technology, propriety bioinformatics platform and highly annotated, analytic capabilities to diagnose mitochondrial disease in children and adults. The Courtagen tests, which are designed to be highly sensitive, efficient and comprehensive, will address the significant need for a quicker, less invasive and more reliable diagnostic tool for this patient population. The company will expand the menu of test options later this year ultimately offering a combination of multiplex proteomic and NGS genomic assays, utilizing Illumina’s MiSeq® and HiSeq® platforms, as they continue rapid expansion of capabilities. Later this year, Courtagen intends to release the first version of its “omics app” that will enhance their physician client’s ability to quickly and easily incorporate the company’s proteomic and genomic testing results into the medical evaluation process.
